Is treatment-resistant depression a unique subtype of depression?

Biological Psychiatry

Volumn 53, Issue 8, 2003, Pages 640-648

  Fagiolini, Andrea ^a   Kupfer, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Comorbidity; Depression; Psychosis; Subtype; TRD; Treatment resistant

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUVOXAMINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETICS; HUMAN; LABORATORY TEST; NEUROBIOLOGY; NEUROIMAGING; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESISTANT DEPRESSION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DIAGNOSTIC IMAGING; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; ENVIRONMENT; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC IMAGING; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; ENVIRONMENT; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PHENOTYPE;

EID: 0038824219     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01670-0     Document Type: Review

References (108)

1. Akiskal HS (1982): Factors associated with incomplete recovery in primary depressive illness. J Clin Psychiatry 43:266-271.
2. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP, Ross RW (2001): Pharmacotherapy of depression in older patients: A summary of the expert consensus guidelines. J Psychiatr Pract 7:361-376.
3. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997): 'Vascular depression' hypothesis. Arch Gen Psychiatry 54:915-922.
4. Alpert JE, Lagomasino IT (2001): Psychiatric comorbidity in treatment-resistant depression. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 430-478.
5. Altshuler LL, Conrad A, Hauser P, Li XM, Guze BH, Denikoff K, et al (1991): Reduction of temporal lobe volume in bipolar disorder: A preliminary report of magnetic resonance imaging. Arch Gen Psychiatry 48:482-483.
6. Arntz A (1999): Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Behav Res Ther 37:S97-S134.
7. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, et al (1993): Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 47:163-173.
8. Basco MR, Rush AJ (1995): Compliance with pharmacotherapy in mood disorders. Psychiatr Ann 25:269-279.
9. Baxter LR Jr, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, et al (1985): Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 42:441-447.
10. Baxter ER Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al (1989): Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46:243-250.
11. Bellivier F, Roy I, Leboyer M (2002): Serotonin transporter gene polymorphisms and affective disorder-related phenotypes. Curr Opin Psychiatry 15:49-58.
12. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ (1993): Regional cerebral blood flow in depression measured by positron emission tomography: The relationship with clinical dimensions. Psychol Med 23:579-590.
13. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, di Bella D, Smeraldi E (1999): Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 156:1450-1452.
14. Bielski RJ, Friedel RO (1976): Prediction of tricyclic antidepressant response: A critical review. Arch Gen Psychiatry 33:1479-1489.
15. Biver F, Goldman S, Delvenne V, Luxen A, De Maertelaer V, Hubain P, et al (1994): Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry 36:381-388.
16. Black DW, Goldstein RB, Nasrallah A, Winokur G (1991): The prediction of recovery using a multivariate model in 1471 depressed inpatients. Eur Arch Psychiatry Clin Neurosci 241:41-45.
17. Blier P, de Montigny C (1998): Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44:313-323.
18. Buysse DJ, Tu XM, Cherry CR, Begley AE, Kowalski J, Kupfer DJ, et al (1999): Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry 45:205-213.
19. Charney DS, Nelson JC (1981): Delusional and nondelusional unipolar depression: Further evidence for distinct subtypes. Am J Psychiatry 138:328-333.
20. Cleare AJ, Murray RM, O'Keane V (1998): Assessment of serotonergic function in major depression using d-fenfluramine: Relation to clinical variables and antidepressant response. Biol Psychiatry 44:555-561.
21. Coffey CE, Wilkinson WE, Weiner RD, Parashos IA, Djang WT, Webb MC, et al (1993): Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Arch Gen Psychiatry 50:7-16.
22. Cohen RM, Semple WE, Gross M, Nordahl TE, King AC, Pickar D, et al (1989): Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia. Neuropsychopharmacology 2:241-254.
23. Coryell W, Tsuang MT (1982): Primary unipolar depression and the prognostic importance of delusions. Arch Gen Psychiatry 39:1181-1184.
24. DeBattista C, Mueller K (2001): Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder? J ECT 17:91-98.
25. Downing RW, Rickels K (1973): Predictors of response to amitriptyline and placebo in three outpatient treatment settings. J Nerv Ment Dis 156:109-129.
26. Brevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, et al (1997): Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824-827.
27. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ML (1992): A functional anatomical study of unipolar depression. J Neurosci 12:3628-3641.
28. Ezquiaga E, Garcia A, Bravo F, Pallares T (1998): Lactors associated with outcome in major depression: A 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol 33:552-557.
29. Fava M, Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF (1994): Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom 62:160-167.
30. Fawcett J, Kravitz HM (1985): Treatment refractory depression. In: Schatzberg AF, editor. Common Treatment Problems in Depression. Washington, DC: American Psychiatric Press, 2-27.
31. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME, et al (2002): Clinical significance of lifetime panic spectrum symptoms in the treatment of bipolar I disorder: A preliminary report. Arch Gen Psychiatry 59:905-911.
32. Frank E, Shear MK, Rucci P, Cyranowski J, Endicott J, Fagiolini A, et al (2000): Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 157:1101-1107.
33. Goodnick PJ, Extein IL (1989): Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1:119-122.
34. Goodwin FK, Jamison KR (1990): Manic-Depressive Illness. New York: Oxford University Press.
35. Grove WM, Andreasen NC (1992): Concepts, diagnosis and classification. In: Paykel ES, editor. Handbook of Affective Disorders, 2nd ed. Edinburgh: Churchill Livingstone, 25-41.
36. Grunhaus L, Shipley JE, Eiser A, Pande AC, Tandon R, Remen A, et al (1996): Polysomnographic studies in patients referred for ECT: Pre-ECT studies. Convuls Ther 12:224-231.
37. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MP, Bennett B (1995): Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 37:151-160.
38. Himmelhoch JM, Detre T, Kupfer DJ, Swartzburg M, Byck R (1972): Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 155:216-220.
39. Himmelhoch JM, Thase ML, Mallinger AG, Houck P (1991): Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910-916.
40. Joyce PR, Paykel ES (1989): Predictors of drug response in depression. Arch Gen Psychiatry 46:89-99.
41. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM (1986): The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow up. Am J Psychiatry 143:24-28.
42. Keller MB, Shapiro RW, Lavori PW, Wolfe N (1982): Relapse in major depressive disorder: Analysis with the life table. Arch Gen Psychiatry 39:911-915.
43. Kim DK, Lim SW, Lee S, Sohn SL, Kim S, Hahn CG, Carroll BJ (2000): Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
44. Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Rowland RH, et al (1999a): Age of onset in chronic major depression: Relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 55:149-157.
45. Klein DN, Schatzberg AF, McCullough JP, Keller MB, Dowling F, Goodman D, et al (1999b): Early- versus late-onset dysthymic disorder: Comparison in out-patients with super-imposed major depressive episodes. J Affect Disord 52:187-196.
46. Kornstein SG, Schneider RK (2001): Clinical features of treatment-resistant depression. J Clin Psychiatry 62(suppl 16):18-25.
47. Koukopoulos A, Koukopoulos A (1999): Agitated depression as a mixed state and the problem of melancholia. Psychiatr Clin North Am 22:547-564.
48. Kronfol Z, Nair M, Goodson J, Goel K, Haskett R, Schwartz S (1989): Natural killer cell activity in depressive illness: Preliminary report. Biol Psychiatry 26:753-756.
49. Kronfol Z, Silva J Jr, Greden J, Dembinski S, Gardner R, Carroll B (1983): Impaired lymphocyte function in depressive illness. Life Sci 33:241-247.
50. Kupfer DJ, First MB, Regier DA, editors (2002): A Research Agenda for DSM-V. Washington, DC: American Psychiatric Association.
51. Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, et al (2000): Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatrica 12:110-114.
52. Kupfer DJ, Spiker DG (1981): Refractory depression: Prediction of non-response by clinical indicators. J Clin Psychiatry 42:307-312.
53. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al (1988): Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45:129-137.
54. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, et al (1993): Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49:11-27.
55. Mallinger AG, Frank E, Barwell MM, Thase ME, Kupfer DJ (1999): Effectiveness of traditional antidepressants is suboptimal in the depressive phase of bipolar disorder. Proceedings of the Annual Meeting of the New Clinical Drug Evaluation Unit Program.
56. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al (1997): Cingulate function in depression: A potential predictor of treatment response. Neuroreport 8:1057-1061.
57. Mervaala E, Föhr J, Könönen M, Valkonen-Korhonen M, Vainio P, Partanen K, et al (2000): Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 30:117-125.
58. Miller PW, Keitner GI, Whisman MA, Ryan CE, Epstein NB, Bishop DS (1992): Depressed patients with dysfunctional families: Description and course of illness. J Abnorm Psychol 101:637-646.
59. Moos RH (1990): Depressed outpatients' life contexts, amount of treatment, and treatment outcome. J Nerv Ment Dis 178:105-112.
60. Nelsen MR, Dunner DL (1995): Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res 29:43-50.
61. Nelson JC, Charney DS (1981): The symptoms of major depressive illness. Am J Psychiatry 138:1-13.
62. Nierenberg AA, Amsterdam JD (1990): Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 51:39-47.
63. Nierenberg AA, Keck P, Samson J, Rothschild AJ, Schatzberg AF (1991): Methodological considerations for the study of treatment-resistant depression. In: Amsterdam JD, editor. Refractory Depression. New York: Raven Press, 1-12.
64. Nunes EV, Deliyannides D, Donovan S, McGrath PJ (1996): The management of treatment resistance in depressed patients with substance use disorders. Psychiatr Clin North Am 19:311-327.
65. O'Reardon JP, Amsterdam JD (1998): Treatment-resistant depression: Progress and limitations. Psychol Ann 28:633-640.
66. O'Reardon JP, Amsterdam JD (2001): Medical disorders and treatment-resistant depression. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 405-429.
67. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF (1996): Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 40:1017-1020.
68. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F (1992): Psychotic (delusional) depression: A meta-analysis of physical treatments. J Affect Disord 24:17-24.
69. Paykel ES (1994): Epidemiology of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, editors. Refractory Depression: Current Strategies and Future Directions. New York: Wiley, 3-18.
70. Paykel ES, Prusoff BA, Klerman GL, Haskell D, DiMascio A (1973): Clinical response to amitriptyline among depressed women. J Nerv Ment Dis 156:149-165.
71. Perris C (1966): A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand (suppl):194.
72. Perry JC, Banon E, Ianni F (1999): Effectiveness of psychotherapy for personality disorders. Am J Psychiatry 156:1312-1321.
73. Petersen T, Gordon JA, Kant A, Fava M, Rosenbaum JF, Nierenberg AA (2001): Treatment resistant depression and axis I co-morbidity. Psychol Med 31:1223-1229.
74. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al (2000): Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
75. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, et al (1993): Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 21(suppl):30-34.
76. Robins E, Guze SB (1970): Establishment of diagnostic validity in psychiatric illness: Its application to schizophrenia. Am J Psychiatry 126:983-987.
77. Rosenbaum JF, Fava M, Nierenberg AA, Sachs GS (2001): Treatment-resistant mood disorders. In: Glenn O, editor. Treatment of Psychiatric Diseases. Washington, DC: American Psychiatric Press, 1307-1383.
78. Roses AD (2000): Pharmacogenetics and the practice of medicine. Nature 405:857-865.
79. Roses AD (2001): Pharmacogenetics. Hum Mol Genet 10:2261-2267.
80. Roy-Byrne PP, Post RM, Kellner CH, Joffe RT, Uhde TW (1988): Ventricular-brain ratio and life course of illness in patients with affective disorder. Psychiatry Res 23:277-284.
81. Rush AJ, Shaw BF (1983): Failures in treating depression by cognitive behavior therapy. In: Foa EB, Emmelkamp PMG, editors. Failures in Behavior Therapy. New York: Wiley Interscience, 217-228.
82. Scott J (1994): Predictors of non-response to antidepressants. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, editors. Refractory Depression: Current Strategies and Future Directions. New York: Wiley, 19-28.
83. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E (2001): Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 6:586-592.
84. Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP (2002): Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatry 180:434-440.
85. Shear MK, Frank E, Rucci P, Fagiolini A, Grochocinski VJ, Houck P, et al (2001): Panic-agoraphobic spectrum: Reliability and validity of assessment instruments. J Psychiatr Res 35:59-66.
86. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al (2001): A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134.
87. Simpson S, Baldwin RC, Jackson A, Burns AS (1998): Is subcortical disease associated with a poor response to anti-depressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 28:1015-1026.
88. Sluzewska A, Rybakowski J, Hornig M, Amsterdam JD (2001): Immunologic factors in treatment resistant depression. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 142-156.
89. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998): Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
90. Soares JC, Mann JJ (1997): The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiatry 41:86-106.
91. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al (1999): Treatment resistant depression: Methodological overview and operational criteria. Eur Neuropsychopharmacol 9:83-91.
92. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al (1985): The pharmacological treatment of delusional depression. Am J Psychiatry 142:430-436.
93. Steffens DC, Conway CR, Dombeck CB, Wagner HR, Tupler LA, Weiner RD (2001): Severity of subcortical gray matter hyperintensity predicts ECT response in geriatric depression. J ECT 17:45-49.
94. Steffens DC, Krishnan KR (1998): Structural neuroimaging and mood disorders: Recent findings, implications for classification, and future directions. Biol Psychiatry 43:705-712.
95. Steimer W, Muller B, Leucht S, Kissling W (2001): Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33-41.
96. Swindle RW Jr, Cronkite RC, Moos RH (1989): Life stressors, social resources, coping, and the 4-year course of unipolar depression. J Abnorm Psychol 98:468-477.
97. Szuba MP, Baxter LR Jrny, Fairbanks LA, Guze BH, Schwartz JM (1991): Effects of partial sleep deprivation on the diurnal variation of mood and motor activity in major depression. Biol Psychiatry 30:817-829.
98. Thase ME (1996): The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Psychiatr Clin North Am 19:287-309.
99. Thase ME (2002): What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 63:95-103.
100. Thase ME, Carpenter L, Kupfer DJ, Frank E (1991): Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull 27:17-22.
101. Thase ME, Kupfer DJ (1987): Characteristics of treatment-resistant depression. In: Zohar J, Belmaker R, editors. Treating Resistant Depression. New York: PMA Publishing, 23-45.
102. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM (1992): Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149:195-198.
103. Thase ME, Rush AJ (1995): Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1081-1098.
104. Videbech P (2000): PET measurements of brain glucose metabolism and blood flow in major depressive disorder: A critical review. Acta Psychiatr Scand 101:11-20.
105. Wolkowitz OM, Reus VI (2001): Psychoneuroendocrine aspects of treatment-resistant mood disorders. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 49-79.
106. Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000): Atypical antipsychotic agents: A critical review. Am J Health Syst Pharm 57:238-255.
107. Worthington J, Fava M, Agustin C, Alpert J, Nierenberg AA, Pava JA, et al (1996): Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics 37:518-522.
108. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000): Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.